GlaxoSmithKline said to be eyeing £1 billion plus takeover bid for Theravance Biopharma, reports The Times

Has GlaxoSmithKline truly given up its pursuit of Aurinia Pharmaceuticals, the US-listed drug developer?

Last year Betaville Intelligence reported that GSK was one of the pharmaceutical giants circling Aurinia but now The Times is reporting the FTSE 100-listed group is looking at a different takeover target...

Register

Register for free to see rest of this article and all public articles from Betaville

Login / Register
Date: Friday, 11 February 2022, 8:21 am

[Disclaimer - the information on Betaville does not consitute any form of investment recommendation and is not intended to be relied upon by readers in making, or refraining from, any investment decisions].

Login to join the conversation